Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Inventory (2016 - 2025)

Historic Inventory for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $196.7 million.

  • Adma Biologics' Inventory rose 1447.37% to $196.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.7 million, marking a year-over-year increase of 1447.37%. This contributed to the annual value of $170.2 million for FY2024, which is 154.48% down from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Inventory is $196.7 million, which was up 1447.37% from $191.5 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Inventory registered a high of $196.7 million during Q3 2025, and its lowest value of $94.1 million during Q1 2021.
  • Moreover, its 5-year median value for Inventory was $163.3 million (2022), whereas its average is $156.1 million.
  • Per our database at Business Quant, Adma Biologics' Inventory skyrocketed by 8005.04% in 2021 and then tumbled by 311.93% in 2025.
  • Over the past 5 years, Adma Biologics' Inventory (Quarter) stood at $124.7 million in 2021, then skyrocketed by 30.91% to $163.3 million in 2022, then rose by 5.9% to $172.9 million in 2023, then fell by 1.54% to $170.2 million in 2024, then rose by 15.53% to $196.7 million in 2025.
  • Its last three reported values are $196.7 million in Q3 2025, $191.5 million for Q2 2025, and $172.2 million during Q1 2025.